Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to DeclineZacks Investment Research • 04/28/26
Wall Street Analysts Believe Alkermes (ALKS) Could Rally 29.14%: Here's is How to TradeZacks Investment Research • 04/28/26
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual MeetingBusiness Wire • 04/16/26
Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical PsychiatryBusiness Wire • 04/14/26
Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2Business Wire • 04/01/26
Alkermes Down Despite Q4 Earnings Beat, Announces Leadership ChangeZacks Investment Research • 02/26/26
Alkermes (ALKS) Reports Q4 Earnings: What Key Metrics Have to SayZacks Investment Research • 02/25/26
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026Business Wire • 02/25/26
Wall Street's Insights Into Key Metrics Ahead of Alkermes (ALKS) Q4 EarningsZacks Investment Research • 02/24/26
Will Alkermes (ALKS) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 02/17/26
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine MarketBusiness Wire • 02/12/26
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026Business Wire • 02/11/26